EP 3478715 A2 20190508 - ANTI-TRANSTHYRETIN ANTIBODIES
Title (en)
ANTI-TRANSTHYRETIN ANTIBODIES
Title (de)
ANTI-TRANSTHYRETIN-ANTIKÖRPER
Title (fr)
ANTICORPS ANTI-TRANSTHYRÉTINE
Publication
Application
Priority
- US 201615201416 A 20160702
- IB 2017053987 W 20170630
Abstract (en)
[origin: WO2018007923A2] The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
IPC 8 full level
C07K 16/18 (2006.01); A61K 39/00 (2006.01)
CPC (source: EP)
A61P 1/00 (2017.12); A61P 9/00 (2017.12); A61P 13/12 (2017.12); A61P 19/00 (2017.12); A61P 19/02 (2017.12); A61P 21/00 (2017.12); A61P 25/00 (2017.12); A61P 25/02 (2017.12); A61P 25/28 (2017.12); A61P 27/02 (2017.12); A61P 29/00 (2017.12); C07K 16/18 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)
Citation (search report)
See references of WO 2018007923A2
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2018007923 A2 20180111; WO 2018007923 A3 20180315; EP 3478715 A2 20190508; JP 2019530427 A 20191024; JP 7016470 B2 20220207
DOCDB simple family (application)
IB 2017053987 W 20170630; EP 17746543 A 20170630; JP 2018568216 A 20170630